Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 9/20 | 0.48 |
| ▸ | NOS2 | P35228 | 9/20 | 0.48 |
| ▸ | NOS1 | P29475 | 6/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190367 | 0.81 | NOS3 (0.46) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL5809638 | 0.81 | NOS3 (0.46) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL20822293 | 0.81 | NOS3 (0.46) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL30684515 | 0.81 | NOS3 (0.46) | NOS3NOS2NOS1CCR1CCR5 | |
| Ammonia Solution, Strong SCHEMBL29016866 | 0.79 | NOS3 (0.44) | NOS3NOS2NOS1CCR1CCR5 | |
| Trifluoromethanesulfonic Acid SCHEMBL18796106 | 0.79 | KCNH2 (0.34) | NOS3NOS2NOS1MAP4K4KDM4E | |
| SCHEMBL13879692 | 0.79 | AGXT (0.55) | NOS3NOS2NOS1USP7ALDH1A1 | |
| SCHEMBL142309 | 0.78 | NOS3 (0.42) | NOS3NOS2NOS1UHRF1MAP4K4 | |
| SCHEMBL30470000 | 0.78 | NOS3 (0.42) | NOS3NOS2NOS1UHRF1MAP4K4 | |
| SCHEMBL21206805 | 0.77 | LMNA (0.44) | NOS3NOS2NOS1CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103103584-B | Plating solution and coating method | 罗门哈斯电子材料有限公司 | 2017-04-05 | — | — | CN | claimed |
| CN-103103584-A | Plating bath and method | ROHM & HAAS ELECT MAT | 2013-05-15 | — | — | CN | claimed |
| US-20250127937-A1 | FAP INHIBITOR | UNIV HEIDELBERG (DE) | 2025-04-24 | — | — | US | disclosed |
| EP-4182320-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-115996926-A | Indole compounds as androgen receptor modulators | 尼多生物科学有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230112012-A1 | FAP INHIBITOR | UNIVERSITAT HEIDELBERG (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-3686199-B9 | FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2022-12-07 | — | — | EP | disclosed |
| CN-108473526-B | Process for producing oligonucleotide and nucleoside, nucleotide or oligonucleotide | 味之素株式会社 | 2022-08-09 | — | — | CN | disclosed |
| CN-113717239-A | Precipitation accelerator and precipitation method using the same | 味之素株式会社 | 2021-11-30 | — | — | CN | disclosed |
| EP-3855519-A2 | STABLE AND EFFICIENT ELECTROLUMINESCENT MATERIALS | Universal Display Corporation (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210038749-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2021-02-11 | — | — | US | disclosed |
| EP-2088861-A2 | BENZIMIDAZOLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| WO-2008051533-A2 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| EP-1763902-A2 | STABLE AND EFFICIENT ELECTROLUMINESCENT MATERIALS | Universal Display Corporation (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20070003789-A1 | Stable and efficient electroluminescent materials | UNIVERSAL DISPLAY CORPORAITON | 2007-01-04 | — | — | US | disclosed |
| WO-2006014599-A2 | STABLE AND EFFICIENT ELECTROLUMINESCENT MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-0517589-B1 | Tachykinin derivatives, their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-12-27 | — | — | EP | disclosed |
| CN-1042906-A | The method for preparing the Quinolonecar boxylic acid intermediate | PFIZER (US) | 1990-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038749-A1 | FAP INHIBITOR | FAP, APC, FIBP | NOS3 4455/4885NOS2 4150/4885NOS1 3789/4885 |
| US-20250127937-A1 | FAP INHIBITOR | FAP, APC, FIBP | NOS3 4455/4885NOS2 4150/4885NOS1 3789/4885 |
| US-20230112012-A1 | FAP INHIBITOR | FAP, APC, FIBP | NOS3 4455/4885NOS2 4150/4885NOS1 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.